StockNews.AI
DCGO
StockNews.AI
15 days

DocGo Inc. (NASDAQ: DCGO) Investor Reminder: Schubert Jonckheer Investigating Possible False Claims, $4 Million in Stock Sales

1. DocGo faces inquiries over alleged false statements by its former CEO. 2. Investors misled about CEO's education and company's contract status. 3. Key lawsuit claims approved by court against DocGo and former CEO. 4. Insiders sold $4 million in stock amid misleading statements. 5. DocGo's stock plummeted 25% after truth regarding CEO's education revealed.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The ongoing lawsuit and revelations indicate severe reputational damage and financial risk. Historically, companies facing similar legal issues often see long-term stock price declines, such as with Enron and Theranos.

How important is it?

The article outlines serious legal challenges and reputational damage that could profoundly impact DCGO.

Why Long Term?

The impact is likely to persist due to trust erosion among investors and legal complexities. Similar past cases have taken years to resolve, hindering recovery.

Related Companies

USMVXLKSPY
, /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP reminds DocGo Inc. (NASDAQ: DCGO) investors that the firm is investigating potential legal claims relating to alleged false statements about the educational background of DocGo's former CEO and the company's business development efforts, and about $4 million in insider stock sales. Current shareholders are encouraged to contact the firm. On March 28, 2025, Judge Katherine Polk Failla of the U.S. District Court for the Southern District of New York ruled that key claims in a securities fraud lawsuit against DocGo and its former CEO could move forward. The lawsuit alleges that between April 2022 and September 2023, DocGo misled investors by stating that its former CEO had a graduate degree in computer science and by misrepresenting DocGo's efforts to enroll migrants in New York Medicaid programs and its business relationship with UnitedHealthcare. Judge Failla found that the complaint sufficiently alleged that the defendants made several "indisputably false" and misleading statements regarding these matters with an intent to defraud. During this period, company insiders sold about $4 million of DocGo stock. After the truth came out in September 2023 that DocGo's former CEO never attended graduate school, DocGo did not enroll anyone in Medicaid, and that UnitedHealthcare did not have a contract with DocGo in New York, DocGo's stock price fell 25%. We are investigating potential wrongdoing by DocGo's directors and officers in connection with these allegations. If you own stock in DocGo, you may have legal options. Visit https://www.classactionlawyers.com/docgo to learn more.About Schubert Jonckheer & Kolbe LLPSchubert Jonckheer & Kolbe represents consumers in class actions against corporate defendants, as well as shareholders in derivative actions against officers and directors. The firm is based in San Francisco and, with the help of co-counsel, litigates cases nationwide.ContactDustin L. Schubert[email protected]Tel: 415-788-4220SOURCE Schubert Jonckheer & Kolbe LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News